Dasatinib, Nilotinib Effective Second-Line Therapy for Chronic Myeloid Leukemia
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
Chronic Myeloid Leukemia
BCR-ABL1 Kinetics Associated With Long-Term TFR Status in Patients With Chronic Myeloid Leukemia
Researchers sought to determine key determinants of sustained treatment-free remission in patients with CML who have completed TKI treatment in an attempt to develop strategies that achieve long-term remission.
Case Study Shows Potential Protective Effect of TKI Therapy for Chronic Myeloid Leukemia
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Molecular Response Maintained With Intermittent Tyrosine Kinase Inhibitor Regimen in Patients With CML
Results of the ongoing OPTkIMA study comparing a fixed and a progressive TKI plan in patients with CML is discussed.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Anti-Emetic Drug Effectively Blocks CD93 Signaling in Preclinical Evaluations, Suggesting Suitability in CML
Investigators assessed the activity of the anti-emetic agent metoclopramide in murine models.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Iclusig Approved for Resistant or Intolerant Chronic-Phase CML
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
AI-Based Model Made Optimal Selections of Frontline TKI Therapy in CML
Investigators report on outcomes for patients with chronic phase CML whose treatment was determined using an artificial intelligence-based model.
STAMP Inhibitor May Be a New Treatment Option in CML
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
- Loading...
Loading...
Loading... 
Loading...